Journal article
Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy
Devy Deliyanti, Saeed F Alrashdi, Sih Min Tan, Colin Meyer, Keith W Ward, Judy B de Haan, Jennifer L Wilkinson-Berka
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | ASSOC RESEARCH VISION OPHTHALMOLOGY INC | Published : 2018
Abstract
Purpose: Oxidative stress is a causal factor in the development of diabetic retinopathy; however, clinically relevant strategies to treat the disease by augmenting antioxidant defense mechanisms have not been fully explored. We hypothesized that boosting nuclear factor erythroid-2-related factor 2 (Nrf2) antioxidant capacity with the novel Nrf2 activator dh404, would protect the retina in diabetes including vision-threatening breakdown of the blood-retinal barrier (BRB) and associated damage to macroglial Müller cells. Methods: Sprague-Dawley rats were randomized to become diabetic or nondiabetic and administered dh404 by gavage for 10 weeks. Complementary in vitro studies were performed in ..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by JDRF post-doctoral fellowship
Awarded by Ministry of Education of Saudi Arabia
Funding Acknowledgements
Supported by Reata Pharmaceuticals, Inc., Irving, TX, USA, during the conduct of this study (DD, JLW-B, JBdH), by The National Health and Medical Research Council (NHMRC) of Australia (#1078442), by a JDRF post-doctoral fellowship (#3-PDF-2017-376-A-N; DD). And by a PhD scholarship from the Ministry of Education of Saudi Arabia (#1021389984; SFA).